List of Excipients in Branded Drug KRAZATI

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Mirati Therapeutics Inc	KRAZATI	adagrasib	80739-812	CELLULOSE, MICROCRYSTALLINE	2043-08-21
Mirati Therapeutics Inc	KRAZATI	adagrasib	80739-812	CROSPOVIDONE	2043-08-21
Mirati Therapeutics Inc	KRAZATI	adagrasib	80739-812	HYPROMELLOSE 2910	2043-08-21
Mirati Therapeutics Inc	KRAZATI	adagrasib	80739-812	MAGNESIUM STEARATE	2043-08-21
Mirati Therapeutics Inc	KRAZATI	adagrasib	80739-812	MALTODEXTRIN	2043-08-21
Mirati Therapeutics Inc	KRAZATI	adagrasib	80739-812	MANNITOL	2043-08-21

KRAZATI Excipient Strategy and Commercial Opportunities: Formulation, Generic Risk, and Patent Protection

Last updated: September 14, 2026

KRAZATI (adagrasib) is an oral KRAS G12C inhibitor marketed by Bristol Myers Squibb after its acquisition of Mirati Therapeutics. Its commercial formulation is a high-frequency, high-dose hard capsule taken at 600 mg twice daily. The principal excipient opportunities are therefore tied to dose-volume reduction, exposure control, gastrointestinal tolerability, capsule performance, and differentiated reformulation rather than biologic stability or parenteral delivery.

KRAZATI received accelerated FDA approval for previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer in December 2022 and regular approval for KRAS G12C-mutated metastatic colorectal cancer after prior treatment with chemotherapy and an anti-VEGF agent in June 2024.[1,2]

What is KRAZATI and how does its formulation affect excipient demand?

KRAZATI contains adagrasib, a covalent inhibitor of KRAS G12C. The approved dose is 600 mg orally twice daily, making it a comparatively high-dose targeted oncology product.[1]

Attribute	KRAZATI
Active ingredient	Adagrasib
Drug class	KRAS G12C inhibitor
Dosage form	Oral hard capsule
Commercial strength	200 mg capsule
Recommended dose	600 mg twice daily
Daily active dose	1,200 mg
U.S. sponsor	Bristol Myers Squibb
Initial U.S. approval	December 2022
Colorectal cancer approval	June 2024
FDA pathway	Accelerated approval in NSCLC; subsequent regular approval in colorectal cancer
Primary formulation challenge	High daily dose with chronic oral administration
Biologic or biosimilar exposure	Not applicable

At the approved dose, patients take three 200 mg capsules per administration and six capsules per day. That creates commercial value for excipient systems that can increase drug loading, improve powder flow, reduce capsule count, reduce food-effect variability, or support a lower-strength or modified-release presentation.

What excipients are used in the approved KRAZATI capsule?

The U.S. prescribing information identifies inactive ingredients including croscarmellose sodium, magnesium stearate, microcrystalline cellulose, sodium lauryl sulfate, and talc. The capsule shell contains gelatin, titanium dioxide, FD&C Blue No. 1, and black iron oxide.[1]

The approved excipient architecture is conventional for an immediate-release hard capsule:

• Microcrystalline cellulose provides bulk and compressibility.
• Croscarmellose sodium supports rapid disintegration.
• Sodium lauryl sulfate can improve wetting of a hydrophobic active ingredient.
• Colloidal or particulate flow aids, where included in the manufacturing composition, can improve blend uniformity and encapsulation.
• Magnesium stearate functions as a lubricant.
• Talc can support flow and processing.
• Gelatin and colorants form the capsule shell.

The commercial opportunity is not necessarily to replace every existing excipient. A more realistic strategy is to develop a higher-load, lower-volume, more robust composition that preserves the exposure profile while reducing manufacturing complexity or pill burden.

What formulation problems create commercial opportunities for KRAZATI?

High dose and capsule burden

KRAZATI requires 1,200 mg of adagrasib per day. At the approved 200 mg strength, the regimen requires six capsules daily. This creates several opportunities:

1. A higher-strength capsule.
2. A tablet or multiparticulate dosage form with higher drug loading.
3. A once-daily formulation if exposure and safety can be maintained.
4. A formulation that reduces gastrointestinal adverse events and improves persistence.
5. A fixed-dose combination with another targeted agent, subject to clinical and regulatory validation.

A higher-strength capsule is technically attractive but may be limited by bulk density, powder flow, fill weight, capsule size, and the quantity of functional excipients required to maintain uniformity.

Solubility, permeability, and food-effect control

Adagrasib is a small molecule with clinically important pharmacokinetic behavior. Formulation work must control dissolution and absorption across gastrointestinal conditions. The label permits administration with or without food, which raises the commercial value of formulations that preserve similar exposure under fed and fasted conditions.[1]

Potential enabling systems include:

• Particle-size reduction.
• Wetting-agent optimization.
• Amorphous solid dispersions.
• Spray-dried dispersions.
• Lipid-based formulations.
• Self-emulsifying drug-delivery systems.
• Co-crystals or alternative solid forms.
• Polymer-assisted supersaturation systems.
• Granulation systems designed for rapid and reproducible dissolution.

Each approach has different patent and manufacturing implications. A lipid-based formulation may improve exposure but create capsule compatibility, oxidation, fill-volume, and scale-up issues. An amorphous dispersion may improve dissolution but introduce physical stability, moisture sensitivity, and recrystallization risks.

Gastrointestinal tolerability

KRAZATI labeling identifies gastrointestinal adverse reactions, including diarrhea, nausea, vomiting, and abdominal symptoms.[1] Excipient strategy can support commercial differentiation if it lowers local gastrointestinal exposure, moderates dissolution, or improves dose tolerability.

Relevant approaches include:

• Delayed or staged release.
• Enteric protection.
• Lower peak concentration through controlled release.
• Reduced surfactant exposure.
• Lower excipient mass.
• Improved dissolution uniformity.
• Reduced exposure to residual solvents or reactive impurities.

A tolerability-focused reformulation would require clinical evidence. A lower adverse-event rate could support lifecycle management, but the regulatory burden would be materially higher than for a conventional generic formulation.

What formulations are protected by KRAZATI-related patents?

KRAZATI’s commercial protection is expected to include composition-of-matter, solid-form, formulation, process, and method-of-use rights. The strongest protection generally comes from the adagrasib compound claims and clinically relevant method claims. Excipient-only claims are usually narrower and more vulnerable to design-around strategies.

Protection category	Commercial purpose	Generic or reformulation relevance
Composition of matter	Protects adagrasib chemical structure	Usually the strongest barrier to early generic entry
Salt, polymorph, or solid form	Controls physical properties and manufacturing	Can delay or complicate alternative API sourcing
Formulation composition	Protects excipient combination or dosage form	May support secondary patent barriers
Dissolution or release profile	Protects performance characteristics	Relevant to modified-release or bioequivalence strategies
Manufacturing process	Protects API or drug-product production	Can create supply-chain barriers but may be avoidable
Method of treatment	Protects use in KRAS G12C cancers	Relevant to label carve-outs and Paragraph IV litigation
Combination therapy	Protects use with chemotherapy, anti-VEGF, or other agents	Supports lifecycle expansion but may be difficult to enforce

Patent numbers, expiration dates, terminal disclaimers, pediatric extensions, and Orange Book listings must be assessed against the current FDA Orange Book and USPTO records. Patent expiry cannot be inferred solely from the drug’s approval date. The relevant date depends on filing history, patent term adjustment, terminal disclaimers, patent-term extension, and any settlement terms.[3,4]

What is the Orange Book status of KRAZATI?

KRAZATI is an FDA-approved small-molecule drug subject to the Hatch-Waxman framework. Its listed patents, if any, can be challenged through an abbreviated new drug application and Paragraph IV certification.[3]

The strategic questions for an ANDA sponsor are:

• Which patents are listed against the approved capsule product?
• Which listed patents claim adagrasib itself?
• Which claims cover only a method of use?
• Are any claims directed to solid forms, formulations, or manufacturing?
• Does a proposed label permit a section viii carve-out?
• Has the NDA holder initiated litigation after receiving a Paragraph IV notice?
• Are there 30-month stays, settlements, or licensed launch dates?
• Does any patent receive pediatric exclusivity or patent-term extension?

An ANDA applicant generally has four certification options for listed patents. A Paragraph IV certification asserts that the patent is invalid, unenforceable, or will not be infringed. The NDA holder can sue within 45 days, potentially triggering a statutory stay of FDA approval for up to 30 months, subject to statutory exceptions and court action.[3]

When does KRAZATI lose exclusivity?

KRAZATI has multiple exclusivity layers rather than a single expiration date.

FDA regulatory exclusivity

The initial NSCLC approval was accelerated. Accelerated approval does not itself create a fixed period of market exclusivity separate from the underlying statutory framework. The colorectal cancer indication received regular approval in 2024.[1,2]

Relevant regulatory protections can include:

• Five-year new chemical entity exclusivity, if applicable.
• Three-year exclusivity for a new clinical investigation supporting an approval.
• Orphan-drug exclusivity, if an indication qualifies and receives designation.
• Pediatric exclusivity, if granted.
• Patent-term extension under 35 U.S.C. §156.

FDA exclusivity records and Orange Book entries should be reviewed by indication and dosage form. Exclusivity attached to one indication may not block all generic approvals if an applicant can use a label carve-out.

Patent exclusivity

Patent expiry may extend beyond regulatory exclusivity. The key commercial issue is whether a generic can obtain approval before the end of the strongest composition-of-matter patent or whether later formulation and method patents create litigation risk.

For investors and licensing parties, the practical endpoint is the earliest credible date on which a legally approved generic can launch, not the earliest date on which an individual patent expires.

Which companies are challenging KRAZATI?

The public competitive challenge to KRAZATI comes primarily from:

• Generic pharmaceutical companies evaluating ANDA entry.
• Developers of alternative KRAS G12C inhibitors.
• Companies developing combination regimens that compete for the same treatment lines.
• Formulation companies offering enabling technologies for lifecycle management.
• Oncology companies developing next-generation KRAS inhibitors active against resistant mutations.

Sotorasib, marketed as LUMAKRAS by Amgen, is the closest commercial comparator in the KRAS G12C class. Both products target KRAS G12C-mutated tumors, but their approved indications, dosing schedules, safety profiles, clinical data, and patent estates differ.[5]

Commercial factor	KRAZATI	LUMAKRAS
Active ingredient	Adagrasib	Sotorasib
Target	KRAS G12C	KRAS G12C
Dosage form	Oral capsule	Oral tablet
Approved NSCLC use	KRAS G12C-mutated locally advanced or metastatic NSCLC after prior systemic therapy	KRAS G12C-mutated locally advanced or metastatic NSCLC after prior systemic therapy
Colorectal cancer use	Approved with cetuximab after prior chemotherapy and anti-VEGF therapy	Regulatory status differs by jurisdiction and indication
Formulation opportunity	High-dose capsule reduction and tolerability optimization	Tablet size, dissolution, and dosing convenience
Biosimilar risk	None	None
Generic risk	ANDA and patent-driven	ANDA and patent-driven

The competitive landscape can shift quickly as next-generation KRAS inhibitors seek activity against G12C resistance mechanisms, brain metastases, or other KRAS mutations. A reformulated KRAZATI product would need to compete against both generic entry and improved targeted therapies.

How strong is the KRAZATI patent estate?

The estate is strongest where claims cover the adagrasib molecular structure, clinically validated use, and commercially necessary manufacturing steps. Formulation claims are strategically useful but often less durable because an ANDA applicant may alter excipients, particle size, capsule shell, or manufacturing sequence.

Patent-strength indicators include:

• Broad, enforceable composition claims.
• Patent term extending materially beyond regulatory exclusivity.
• Claims covering the approved dose and indication.
• Limited freedom to design around solid-form or formulation claims.
• Validated clinical relevance of the claimed formulation.
• Manufacturing claims that are difficult to avoid at commercial scale.
• Active Orange Book listings.
• No adverse validity ruling or narrowing prosecution history.

Manufacturing patents can be commercially significant even when they do not block all generic entry. A generic sponsor may need to qualify a different API process, solid form, impurity-control strategy, or drug-product manufacturing route. That can increase development time and technical risk without creating an absolute legal barrier.

What excipient licensing opportunities exist for KRAZATI?

The most attractive licensing opportunities fall into five categories.

High-loading capsule technologies

A technology that increases adagrasib loading while maintaining blend uniformity and dissolution could reduce capsule count. Value drivers include smaller capsule size, lower fill weight, reduced lubricant dependence, and stable manufacturing performance.

Amorphous dispersion platforms

A stable dispersion could improve dissolution and reduce variability. The licensing case is strongest if the platform supports a clinically differentiated profile or enables a smaller dosage form.

Modified-release systems

A controlled-release formulation could reduce peak-related tolerability issues or support once-daily administration. This would require substantial pharmacokinetic and clinical development.

Taste and swallowability technologies

Taste masking has limited relevance to an intact hard capsule but becomes important for sprinkle formulations, oral granules, pediatric development, and patients with swallowing difficulties.

Capsule-shell and sustainability systems

Plant-based capsule shells, lower-colorant systems, or moisture-resistant shells could reduce supply-chain and environmental burdens. These changes are commercially secondary unless they improve stability, patient acceptability, or manufacturing yield.

A licensor should seek claims directed to measurable performance, such as dissolution, exposure, particle-size distribution, content uniformity, or stability, rather than relying solely on a list of excipients.

What generic entry risks exist for KRAZATI?

Generic entry risk is driven by three pathways:

1. An ANDA referencing the approved capsule.
2. A Paragraph IV challenge to listed patents.
3. A later reformulation or alternative dosage form that avoids key formulation claims.

The highest-risk scenario for the originator is an ANDA that uses the same active ingredient and achieves bioequivalence while avoiding secondary formulation patents. The highest-value defense is a valid composition patent or a clinically relevant formulation patent that is difficult to design around.

Potential launch scenarios include:

Scenario	Commercial effect
No Paragraph IV challenge before core patent expiry	Originator retains protection until patent or exclusivity endpoint
Paragraph IV settlement with delayed entry	Predictable erosion date; possible licensed generic
Court invalidates or narrows core patent	Accelerated generic competition
Label carve-out for method patents	Generic may enter selected indications
Authorized generic launch	Price erosion with controlled channel access
Reformulated originator product	May preserve premium pricing but requires clinical and regulatory investment
Competing KRAS therapy gains preference	Revenue erosion before generic entry

What is the revenue exposure and commercial opportunity?

KRAZATI revenue is exposed to three separate pressures: generic entry, competition from LUMAKRAS and next-generation KRAS drugs, and treatment-line movement caused by new combination regimens.

Excipient-driven lifecycle management can protect revenue if it achieves one of four outcomes:

• Improves adherence through fewer capsules.
• Reduces treatment discontinuation.
• Expands use to patients unable to swallow capsules.
• Creates a new dosage form with independent patent and regulatory value.

A simple excipient substitution is unlikely to justify premium pricing. A reformulation that supports once-daily dosing, materially improves tolerability, or reduces capsule burden has a stronger commercial case.

Key Takeaways

• KRAZATI is a high-dose oral capsule containing adagrasib, with a recommended dose of 600 mg twice daily.
• The principal excipient opportunities are higher drug loading, capsule-count reduction, dissolution control, exposure consistency, and gastrointestinal tolerability.
• A biologic or biosimilar strategy is not relevant because KRAZATI is a small-molecule drug.
• The most valuable formulation programs should generate measurable clinical or pharmacokinetic differentiation.
• Generic risk will depend on Orange Book listings, composition-of-matter protection, Paragraph IV activity, litigation outcomes, and label carve-outs.
• Formulation and excipient patents can delay or complicate entry but are generally more design-around-prone than compound patents.
• The strongest licensing opportunities involve high-loading capsules, amorphous dispersions, modified release, and patient-friendly alternative dosage forms.
• KRAZATI competes most directly with sotorasib and indirectly with next-generation KRAS inhibitors and combination regimens.

FAQs

Can KRAZATI be reformulated as a once-daily product?

Potentially, but once-daily development would require a new pharmacokinetic and clinical package. The existing 600 mg twice-daily regimen creates a formulation rationale, but modified release would need to preserve efficacy and control toxicity.

Do KRAZATI excipients create an independent generic barrier?

Usually not by themselves. Excipients can support a formulation patent, but a generic applicant may use different inactive ingredients if it can demonstrate pharmaceutical equivalence, bioequivalence, and compliance with FDA requirements.

Is adagrasib suitable for an amorphous solid dispersion?

It may be technically suitable if dissolution or solubility limits the conventional capsule formulation. Development would need to address physical stability, recrystallization, moisture uptake, residual solvents, and scale-up.

Can a generic omit the colorectal cancer indication?

Possibly. A generic applicant may seek a label carve-out for a patented method of use if the remaining label is legally and medically acceptable. The result depends on the specific patents, labeling language, and FDA requirements.

Would a higher-strength KRAZATI capsule materially improve commercial value?

Yes, if it reduces capsule burden without creating larger capsules, poor content uniformity, slower dissolution, or new safety concerns. A 600 mg single-dose presentation could reduce daily capsule count, but its feasibility depends on powder density and drug-product performance.

References

1. U.S. Food and Drug Administration. (2024). KRAZATI (adagrasib) prescribing information. Bristol Myers Squibb.

2. U.S. Food and Drug Administration. (2024, June 21). FDA approves adagrasib with cetuximab for colorectal cancer. https://www.fda.gov/

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

4. United States Patent and Trademark Office. (2024). Patent term adjustment and patent term extension information. https://www.uspto.gov/

5. U.S. Food and Drug Administration. (2024). LUMAKRAS (sotorasib) prescribing information. Amgen.